Aurinia Pharmaceuticals
World Rank (Jan-05-2024)
7,666
Market Cap (Jan-05-2024)
1.213 Billion USD
World Rank (Jul-30-2023)
6,232
Market Cap (Jul-30-2023)
1.755 Billion USD
World Rank (Dec-25-2022)
10,850
Market Cap (Dec-25-2022)
0.644 Billion USD
World Rank (Jan-07-2022)
5,556
Market Cap (Jan-07-2022)
2.44 Billion USD
Annual Revenue in USD
35 Million USD
Annual Net Income in USD
-138 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Company Profile
Aurinia Pharmaceuticals is a Clinical Stage Biopharmaceutical company. The company developing in voclosporin, an investigational therapy for the treatment of lupus nephritis and other proteinuric diseases. The headquarters is in Canada.
Company Website